Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:

  • Phase 1b/2a immune thrombocytopenia (ITP) trial FPI achieved, enrollment ongoing.
  • Phase 1b systemic lupus erythematosus (SLE) trial FPI achieved, enrollment ongoing.
  • Phase 2 primary membranous nephropathy (pMN) trial will initiate in the coming weeks.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.